Radiofarmaceutyki stosowane w badaniach onkologicznych: przegląd.

Monika Pławska; Witold Cholewiński

doi:10.21641/los.2026.1.1.273

Tom 23 Nr 2 (2026), Prace poglądowe

Tom 23 Nr 2 (2026)

Radiofarmaceutyki stosowane w badaniach onkologicznych: przegląd.

Prace poglądowe

Opublikowane 29-05-2026

Monika Pławska
Witold Cholewiński

Monika Pławska

Witold Cholewiński

PDF

Słowa kluczowe

diagnostyka
medycyna nuklearna
onkologia
radiofarmaceutyki
terapia

Jak cytować

Pławska, Monika, i Witold Cholewiński. 2026. „Radiofarmaceutyki Stosowane W Badaniach Onkologicznych: Przegląd”. Zeszyty Naukowe WCO 23 (2). https://doi.org/10.21641/los.2026.1.1.273.

Abstrakt

Radiofarmaceutyki to leki, składające się zwykle z radioizotopu i ligandu, czyli nośnika biologicznego. Zastosowania preparatów radiofarmaceutycznych obejmują zarówno diagnostykę, jak i terapię, czy w końcu – rozwijającą się obecnie Teranostykę. Niniejsze opracowanie stanowi podsumowanie obecnego stanu wiedzy w zakresie zastosowań radiofarmaceutyków w onkologii.

PDF

Bibliografia

[1] Fahey F, Grant F. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz. J Appl Clin Med Phys 2021;22:4-10.

[2] Ehrhardt JD Jr, Güleç S. A review of the history of radioactive iodine theranostics: the origin of nuclear ontology. Mol Imaging Radionucl Ther. 2020;29(3):88-97.

[3] Varghese T, John A, Mathew J. Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy. Precis Radiat Oncol 2024;8:145-152.

[4] Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P i in. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem 2021;6:8.

[5] Zhang S, Wang X, Gao X, Chen X, Li L, Li G i in. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther 2025;10(1):1.

[6] Trägårdh M, Møller N, Sørensen M. Methodologic considerations for quantitative 18F-FDG PET/CT studies of hepatic glucose metabolism in healthy subjects. J Nucl Med. 2015;56:1366-1371.

[7] Patching SG. Roles of facilitative glucose transporter GLUT1 in [¹⁸F]FDG positron emission tomography (PET) imaging of human diseases. J Diagn Imaging Ther 2015;2:30-102.

[8] Wang Y, Shao G, Wu J, Cui C, Zang S, Qiu F i in. Preparation of 68Ga‑PSMA‑11 with a Synthesis Module for Micro PET‑CT Imaging of PSMA Expression during Prostate Cancer Progression. Contrast Media Mol Imaging 2018;2018:8046541.

[9] Cacko M, Jóźwik‑Plebanek K, Wnuk J, Teresińska A. Incidental finding of [99mTc]Tc‑MIBI uptake in a post‑radiotherapy breast without recurrence of cancer. Nucl Med Rev Cent East Eur 2023;26(0):156‑157.

[10] Hofman MS, Iravani A. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clin 2017;12:219-234.

[11] Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T i in. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-833.

[12] Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M i in. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med 2020;45(1):19-31.

[13] Sun Y-Q, Sun D, Zhang X, Zhang Y-Q, Lin Y-S. Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration. Front Endocrinol (Lausanne) 2022;13:994288.

[14] Das S, Al-Toubah T, El-Haddad G, Strosberg J i in. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumours. Expert Rev Gastroenterol Hepatol 2019;13(11):1023-1031.

[15] Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M i in. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics 2021;11(16):7911-7947.

[16] Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F i in. An overview of targeted alpha therapy with 225 Ac and 213 Bi. Curr Radiopharm 2018;11(3):200-208.

[17] Ku A, Facca VJ, Cai Z, Reilly RM i in. Auger electrons for cancer therapy — a review. EJNMMI Radiopharm Chem 2019;4(1):27.

[18] Monfared YK, Heidari P, Klempner SJ, Mahmood U, Parikh AR, Hong TS i in. DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics 2023;15(12):2761.

[19] European Directorate for the Quality of Medicines & HealthCare. Guide for the elaboration of monographs on radiopharmaceutical preparations. Strasbourg: EDQM; 2018.

[20] Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci 2023;24:11626.

[21] Westerbergh F, van der Meulen NP, Müller C, Grings A, Ritt P, Bernhardt P. Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls. EJNMMI Res 2025;15(1):13.

[22] Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H i in. 225Ac-PSMA-617/ 177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 2020;47:721-728.

[23] Cheng Z, Chen P, Yan J. A review of state-of-the-art resolution improvement techniques in SPECT imaging. EJNMMI Phys 2025;12:9.

[24] Alberts I, Sari H, Mingels C, Afshar-Oromieh A, Pyka T, Shi K i in. Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imaging 2023;23:28.

[25] Schaefferkoetter J, Shah V, Hayden C, Prior JO, Zuehlsdorff S. Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data. Eur J Nucl Med Mol Imaging 2023;50:2292-2304.

[26] Olin AB, Hansen AE, Rasmussen JH, Jakoby B, Berthelsen AK, Ladefoged CN i in. Deep learning for Dixon MRI-based attenuation correction in PET/MRI of head and neck cancer patients. EJNMMI Phys 2022;9:20.